Skip to main content

Trivaris FDA Approval History

Last updated by Judith Stewart, BPharm on Jan 27, 2021.

FDA Approved: Yes (Discontinued) (First approved June 16, 2008)
Brand name: Trivaris
Generic name: triamcinolone acetonide
Dosage form: Intravitreal Injection
Company: Allergan plc
Treatment for: Ocular Inflammatory Conditions

Marketing Status: Discontinued

Trivaris (triamcinolone acetonide) is a glucocorticoid corticosteroid delivered via intravitreal injection for the treatment of sympathetic ophthalmia, temporal arteritis, uveitis, and ocular inflammatory conditions unresponsive to topical corticosteroids.

Development timeline for Trivaris

Jun 17, 2008Approval Allergan Receives U.S. Food and Drug Administration Approval for Trivaris (triamcinolone acetonide injectable suspension) 80 mg/mL

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.